AR107937A1 - Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer - Google Patents

Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer

Info

Publication number
AR107937A1
AR107937A1 ARP170100697A ARP170100697A AR107937A1 AR 107937 A1 AR107937 A1 AR 107937A1 AR P170100697 A ARP170100697 A AR P170100697A AR P170100697 A ARP170100697 A AR P170100697A AR 107937 A1 AR107937 A1 AR 107937A1
Authority
AR
Argentina
Prior art keywords
compounds
salts
formula
cinolin
amina
Prior art date
Application number
ARP170100697A
Other languages
English (en)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR107937A1 publication Critical patent/AR107937A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El uso de dichos compuestos y las sales de los mismos para tratar o prevenir las enfermedades mediadas por la quinasa ATM, incluyendo cáncer. Formas cristalinas de los compuestos de la fórmula (1) y las sales de los mismos aceptables desde el punto vista farmacéutico; las composiciones farmacéuticas que comprenden dichos compuestos y las sales de los mismos, los kits que comprenden dichos compuestos y las sales de los mismos, los métodos de manufactura de dichos compuestos y las sales de los mismos; los compuestos intermedios útiles en la manufactura de dichos compuestos y las sales de los mismos; y con los métodos de tratamiento de las enfermedades mediadas por la quinasa ATM, incluyendo cáncer, utilizando los compuestos de la fórmula (1) y las sales de los mismos solos o en combinación con otras terapias. Reivindicación 1: Un compuesto de la fórmula (1), o una sal del mismo aceptable desde el punto vista farmacéutico, en donde: R¹ es alquilo C₁₋₃; R² es hidro o alquilo C₁₋₃; o R¹ y R² junto con el átomo de nitrógeno al cual ellos están enlazados forman un anillo de azetidinilo, pirrolidinilo, o piperidinilo; y R³ es hidro o metilo.
ARP170100697A 2016-03-21 2017-03-21 Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer AR107937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662310883P 2016-03-21 2016-03-21

Publications (1)

Publication Number Publication Date
AR107937A1 true AR107937A1 (es) 2018-06-28

Family

ID=58361025

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100697A AR107937A1 (es) 2016-03-21 2017-03-21 Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer

Country Status (18)

Country Link
US (1) US20190099421A1 (es)
EP (1) EP3433251A1 (es)
JP (1) JP2019512512A (es)
KR (1) KR20180127419A (es)
CN (1) CN108884084A (es)
AR (1) AR107937A1 (es)
AU (1) AU2017237394A1 (es)
BR (1) BR112018068347A2 (es)
CA (1) CA3017035A1 (es)
CO (1) CO2018010951A2 (es)
DO (1) DOP2018000197A (es)
IL (1) IL261648A (es)
MA (1) MA43733A (es)
MX (1) MX2018011283A (es)
PE (1) PE20181895A1 (es)
SG (1) SG11201806982PA (es)
TW (1) TW201808939A (es)
WO (1) WO2017162605A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111344293A (zh) * 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
US20210353614A1 (en) * 2018-03-14 2021-11-18 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
CA3111994A1 (en) * 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2h-imidazo[4,5-c]cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
WO2021260580A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
CN103339110A (zh) 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012162254A1 (en) * 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
NO2714752T3 (es) * 2014-05-08 2018-04-21

Also Published As

Publication number Publication date
TW201808939A (zh) 2018-03-16
MX2018011283A (es) 2019-05-27
SG11201806982PA (en) 2018-09-27
IL261648A (en) 2018-10-31
EP3433251A1 (en) 2019-01-30
DOP2018000197A (es) 2018-10-15
PE20181895A1 (es) 2018-12-11
CO2018010951A2 (es) 2018-10-22
US20190099421A1 (en) 2019-04-04
MA43733A (fr) 2018-11-28
AU2017237394A1 (en) 2018-11-01
BR112018068347A2 (pt) 2019-01-15
KR20180127419A (ko) 2018-11-28
CN108884084A (zh) 2018-11-23
WO2017162605A1 (en) 2017-09-28
CA3017035A1 (en) 2017-09-28
JP2019512512A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
CL2019002150A1 (es) Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY36285A (es) Compuestos que inhiben la proteína mcl-1
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR094553A1 (es) Formas de oxadiazolpirazina
AR100006A1 (es) Derivados de tubulisina
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR107937A1 (es) Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
NI201800071A (es) Compuestos de isoindol
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
AR109108A1 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure